Benjamin Hindson Sells 7,826 Shares of 10x Genomics (NASDAQ:TXG) Stock

10x Genomics (NASDAQ:TXG) insider Benjamin Hindson sold 7,826 shares of the business’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $18.58, for a total transaction of $145,407.08. Following the transaction, the insider directly owned 424,779 shares of the company’s stock, valued at approximately $7,892,393.82. This represents a 1.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

10x Genomics Stock Performance

10x Genomics stock opened at $22.13 on Friday. 10x Genomics has a 52 week low of $6.78 and a 52 week high of $23.56. The firm has a market capitalization of $2.83 billion, a PE ratio of -63.23 and a beta of 2.24. The business’s 50-day simple moving average is $19.19 and its 200-day simple moving average is $15.98.

10x Genomics (NASDAQ:TXG) last announced its earnings results on Thursday, February 12th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.06. The firm had revenue of $166.03 million during the quarter, compared to the consensus estimate of $160.35 million. 10x Genomics had a negative return on equity of 6.89% and a negative net margin of 6.77%.The firm’s revenue for the quarter was up .6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.40) EPS. Research analysts forecast that 10x Genomics will post -1.43 earnings per share for the current year.

10x Genomics News Summary

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: Quarterly results beat expectations: 10x reported revenue and an EPS beat in its Feb. 12 quarter (revenue roughly $166M, EPS better than consensus), which supports upside momentum and underpins recent analyst target increases. MarketBeat TXG Coverage
• Positive Sentiment: Analyst updates lifted sentiment: Several firms nudged price targets higher or reiterated constructive stances (examples cited include TD Cowen, Stifel, UBS and Canaccord), giving traders cover to buy after the earnings beat. Analyst Note
• Neutral Sentiment: Short‑interest reports appear unreliable: data entries show a large “increase” but list 0 shares / NaN and a 0.0 days‑to‑cover figure — likely a reporting glitch. This makes short‑interest an unclear signal for near‑term pressure. (No reliable link available in the alert feed.)
• Negative Sentiment: Insiders sold a material block of shares last week: CEO Serge Saxonov, CFO Adam Taich and other executives sold shares on Feb. 23 (multi‑thousand share dispositions; examples: CEO ~9,632 shares, CFO ~8,968, Benjamin Hindson ~7,826). Large insider sales can weigh on sentiment and prompt investor caution even if labeled routine diversification. InsiderTrades Alert TipRanks Coverage

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TXG. Allworth Financial LP boosted its holdings in 10x Genomics by 150.4% during the second quarter. Allworth Financial LP now owns 2,271 shares of the company’s stock valued at $26,000 after purchasing an additional 1,364 shares in the last quarter. Geneos Wealth Management Inc. bought a new position in shares of 10x Genomics during the 4th quarter worth approximately $38,000. Larson Financial Group LLC boosted its stake in 10x Genomics by 164.4% in the 4th quarter. Larson Financial Group LLC now owns 2,364 shares of the company’s stock valued at $39,000 after buying an additional 1,470 shares in the last quarter. True Wealth Design LLC boosted its stake in 10x Genomics by 1,552.5% in the 2nd quarter. True Wealth Design LLC now owns 3,586 shares of the company’s stock valued at $42,000 after buying an additional 3,369 shares in the last quarter. Finally, Van ECK Associates Corp grew its position in 10x Genomics by 85.9% in the fourth quarter. Van ECK Associates Corp now owns 3,668 shares of the company’s stock valued at $60,000 after acquiring an additional 1,695 shares during the period. Institutional investors own 84.68% of the company’s stock.

Wall Street Analyst Weigh In

TXG has been the subject of a number of research reports. TD Cowen increased their price target on shares of 10x Genomics from $18.00 to $19.00 and gave the company a “hold” rating in a report on Friday, February 13th. Leerink Partners cut their price objective on shares of 10x Genomics from $22.00 to $20.00 and set a “market perform” rating for the company in a research report on Tuesday, January 27th. Bank of America set a $21.00 target price on shares of 10x Genomics in a research note on Monday, January 12th. Barclays boosted their price target on 10x Genomics from $17.00 to $22.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $20.00 price target (up from $17.00) on shares of 10x Genomics in a report on Monday, December 1st. Four analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $18.11.

10x Genomics Company Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.